Peptides have moved from the fringes of "biohacking" forums into mainstream telehealth menus faster than almost any therapeutic category since GLP-1s. The regulatory picture is contradictory. Federal health leadership has publicly championed broader peptide access, and an FDA advisory committee recently voted to open a lawful compounding pathway for several popular compounds. Over the same period, FDA, the FTC, and state attorneys general have stepped up enforcement against t